A5024622557- Breast Cancer Treatment Studies
- HER2/EGFR in Cancer Research
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Radiomics and Machine Learning in Medical Imaging
- Advanced Breast Cancer Therapies
- Cancer Cells and Metastasis
- RNA modifications and cancer
- Estrogen and related hormone effects
- BRCA gene mutations in cancer
- Cancer-related Molecular Pathways
- Medical Imaging Techniques and Applications
- Bioinformatics and Genomic Networks
- Cancer Immunotherapy and Biomarkers
- Breast Lesions and Carcinomas
- Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Ferroptosis and cancer prognosis
- Glutathione Transferases and Polymorphisms
- Gene expression and cancer classification
- Colorectal Cancer Treatments and Studies
- Mechanisms of cancer metastasis
- Epigenetics and DNA Methylation
- Lung Cancer Treatments and Mutations
- Monoclonal and Polyclonal Antibodies Research
Karolinska Institutet
2015-2024
Karolinska University Hospital
2015-2024
UNC Lineberger Comprehensive Cancer Center
2017
Sophiahemmet Hospital
2004-2017
Sahlgrenska University Hospital
2010-2017
Virginia Commonwealth University
2017
Skåne University Hospital
2017
University of Helsinki
2016
University of Sulaimani
2015
May Institute
2015
PURPOSE To compare two doses of letrozole and megestrol acetate (MA) as second-line therapy in postmenopausal women with advanced breast cancer previously treated antiestrogens. PATIENTS AND METHODS Five hundred fifty-one patients locally advanced, locoregionally recurrent or metastatic were randomly assigned to receive 2.5 mg (n = 174), 0.5 188), MA 160 189) once daily a double-blind, multicenter trial. Data analyzed for tumor response safety variables up 33 months follow-up evaluation...
PURPOSE To investigate whether hormonal receptors and human epidermal growth factor receptor 2 (HER2) change throughout tumor progression, because this may alter patient management. PATIENTS AND METHODS The study cohort included female patients with breast cancer in the Stockholm health care region who relapsed from January 1, 1997, to December 31, 2007. Either biochemical or immunohistochemical (IHC)/immunocytochemical (ICC) methods were used determine estrogen (ER), progesterone (PR), HER2...
Cytotoxic T cells infiltrating tumors are thought to utilize HIF transcription factors during adaptation the hypoxic tumor microenvironment. Deletion analyses of two key isoforms found that HIF-1α, but not HIF-2α, was essential for effector state in CD8+ cells. Furthermore, loss HIF-1α reduced infiltration and cell killing, altered vascularization. VEGF-A, an target gene, accelerated tumorigenesis while also altering Analyses human breast cancer showed inverse correlations between VEGF-A...
•KAMILLA exploratory analysis suggests T-DM1 is active and well tolerated in HER2-positive MBC with brain metastases (BM).•Overall response rate was 21.4% (27/126) across all organs patients measurable BM.•Brain target lesion responses were observed without prior radiotherapy.•In 398 baseline BM treated T-DM1, median progression-free survival 5.5 (95% CI, 5.3–5.6) months.•Safety generally similar versus BM, except for nervous system adverse events. BackgroundPatients (BM) from human...
Although metabolic reprogramming within tumor cells and microenvironment (TME) is well described in breast cancer, little known about how the interplay of immune state cancer metabolism evolves during treatment. Here, we characterize immunometabolic profiles tissue samples longitudinally collected from individuals with before, after neoadjuvant chemotherapy (NAC) using proteomics, genomics histopathology. We show that pre-, on-treatment dynamic changes state, proteins cell gene expression...
Background. Response Evaluation Criteria In Solid Tumors (RECIST) and WHO-criteria are used to evaluate treatment effects in clinical trials. The purpose of this study was examine interobserver intraobserver variations radiological response assessment using these criteria. Material methods. Thirty-nine patients were eligible. Each patient's series CT images reviewed. patient classified into one four categories according RECIST WHO-criteria. To variation, classifications independently...
We and others have recently shown that tumor characteristics are altered throughout progression. These findings emphasize the need for re-examination of at relapse led to recommendations from ESMO Swedish Breast Cancer group. Here, we aim determine whether molecular subtypes in breast cancer metastases confer clinically relevant prognostic information patients.
Pathologic complete response (pCR) is a predictor for favorable outcome after neoadjuvant treatment in early breast cancer. Modulation of gene expression may also provide readouts biological activity and prognosis, offering the possibility timely response-guided adjustment. The role transcriptional changes predicting to chemotherapy plus bevacizumab was investigated. One-hundred-and-fifty patients with large, operable locally advanced HER2-negative cancer received epirubicin docetaxel,...
<h3>Importance</h3> Trastuzumab emtansine (T-DM1) is presently approved for treatment of advanced breast cancer and after incomplete response to neoadjuvant therapy, but the potential T-DM1 as monotherapy so far unknown. <h3>Objective</h3> To assess pathologic complete (pCR) standard therapy combination docetaxel, trastuzumab, pertuzumab (DTP) vs in patients with ERBB2 (formerly HER2)-positive cancer. <h3>Design, Setting, Participants</h3> This randomized phase 2 trial, conducted at 9 sites...
Determinants of papillary thyroid cancer were evaluated in a questionnaire-based case-control study from southeastern Sweden. A total 104 cases, diagnosed 1977 to 1987, and 387 randomly selected controls included the analyses. Female subjects with reported work history as dentists/dental assistants, telephone operators, teachers, day nursery personnel, an occupational contact chemicals video display terminals more often than did controls. The 11 male cases working mechanics metal workers...
Background Predicting any future metastatic site of early‐stage breast cancer is important as it significantly influences the prognosis advanced disease. This study aimed at investigating potential claudin‐2, over‐expressed in liver metastases, a biomarker for predicting propensity primary cancer. Methods Claudin‐2 expression was analyzed two independent cohorts. Cohort 1 included 304 women with diagnosed between 2002 and 2007, while cohort 2 237 premenopausal node‐negative 1991 1994. Global...
Transcriptomic profiles have shown promise as predictors of response to neoadjuvant chemotherapy in breast cancer (BC). This study aimed explore their predictive value the advanced BC (ABC) setting.In a Phase 3 trial first-line ABC, fine needle aspiration biopsy (FNAB) was obtained at baseline. Intrinsic molecular subtypes and gene modules related immune response, proliferation, oestrogen receptor (ER) signalling recurring genetic alterations were analysed for association with objective...
The seed and soil hypothesis was proposed over a century ago to describe why cancer cells (seeds) grow in certain organs (soil). Since then, the genetic properties that define have been heavily investigated; however, genomic mediators within organ microenvironment mediate successful metastatic growth are less understood. These studies sought identify cancer- organ-specific programs metastasis. In these studies, set of 14 human breast patient-derived xenograft (PDX) metastasis models...
Following chemotherapy and human epidermal growth factor 2 (HER2)-targeted neoadjuvant therapy for HER2-positive early breast cancer, residual invasive cancer at surgery may be HER2-negative on retesting in some patients. We evaluated outcomes with T-DM1 trastuzumab patients randomized the phase III KATHERINE trial based central testing of pre-treatment core biopsy their corresponding surgical specimen after treatment. In 70/845 (8.3%) disease surgery, there were 11 IDFS events 42...
Abstract Purpose: PREDIX HER2 is a randomized Phase II trial that compared neoadjuvant docetaxel, trastuzumab, and pertuzumab (THP) with trastuzumab emtansine (T-DM1) for HER2-positive breast cancer. Rates of pathologic complete response (pCR) did not differ between the two groups. Here, we present survival outcomes from investigate metabolic tumor-infiltrating lymphocytes (TIL) as prognostic factors. Patients Methods: In total, 202 patients cancer were enrolled 197 received six cycles...
The complete molecular basis of the organ-specificity metastasis is elusive. This study aimed to provide an independent characterization transcriptional landscape breast cancer metastases with specific objective identify liver metastasis-selective genes prognostic importance following primary tumor diagnosis.A cohort 304 women advanced was studied. Associations between site recurrence and clinicopathologic features were investigated. Fine-needle aspirates (n = 91) subjected whole-genome...